Molecular basis of diseases and molecular target

Leader of the research programme:

  • Professor Jiří Bártek, MD., PhD.
  • Professor Martin Petřek, PhD.

Reaearch program aims at identification and description of metabolic pathways, signaling pathways, genetic and epigenetic changes causing human diseases that are within scope of the project. These include: cancers of different origin and infectious/inflammatory diseases. Results obtained will help in selecting a target molecule, most frequently a protein, through which it is possible to influence the disease. In case of carcinomas, molecular target-based therapy leads to enhanced efficacy of anticancer drugs while minimizing their negative effects, because blocking molecular processes results in cancer cells depletion usually via natural programmed cell death that is not accompanied by toxic effects. Major part of the research will comprise identification of signaling pathways of DNA damage in human cells, their coordination with mechanisms of DNA repair as well as specific detection of posttranslational modifications (especially phosphorylations) and changes in distribution of activated proteins responding to DNA damage. Key person of this workpackage will be Jiří Bártek. Project BIOMEDREG will help immensely to stabilize his research group in the Czech Republic and will permit establishment of a school endeavoring in genome integrity problems and early carcinogenesis processes on a world class level.
Deliverables: 1. Identification of novel genes/pathways involved in the process of control and maintenance of genomic integrity; 2. Novel methodical protocols allowing investigation and monitoring of influence of environmental factors on genomic integrity in humans; 3. Genetic, epigenetic and proteomic changes in health and disease – identification of novel molecular targets an pathophysiology in cancer and infectious diseases. Deliverables will be published in the form of papers, research reports, patents and conference presentations.
Key methodological approaches: Genomics, proteomics, metabolomics, pan-genome screening for molecular targets